Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant EC and paclitaxel with or without gemcitabine in high-risk early breast cancer
ISRCTN78234870Phase 3Completed
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Apr 2000
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of epirubicin, cyclophosphamide, paclitaxel and gemcitabine in breast cancer (4 arms), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoint: Pathological complete response after 4 courses. Started Apr 2000; status: completed.
02
Drugs
epirubicincyclophosphamidepaclitaxelgemcitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN78234870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN78234870.